Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

@article{Pignon2008LungAC,
  title={Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.},
  author={Jean Pierre Pignon and H{\'e}l{\`e}ne Tribodet and Giorgio V Scagliotti and Jean-Yves Douillard and Frances A. Shepherd and Richard J. Stephens and Ariane Dunant and Valter Torri and Rafael Rosell and Lesley K Seymour and Stephen G. Spiro and Estelle Rolland and Roldano Fossati and Delphine Aubert and Keyue Ding and David A. Waller and Thierry le Chevalier},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 21},
  pages={
          3552-9
        }
}
PURPOSE Several recent trials have shown a significant overall survival (OS) benefit from postoperative cisplatin-based chemotherapy in patients with non-small-cell lung cancer (NSCLC). The aim of the Lung Adjuvant Cisplatin Evaluation was to identify treatment options associated with a higher benefit or groups of patients who particularly benefit from postoperative chemotherapy. PATIENTS AND METHODS Individual patient data were collected and pooled from the five largest trials (4,584… Expand

Paper Mentions

Interventional Clinical Trial
The proposed study will evaluate the safety and feasibility of preoperative administration nivolumab +/- ipilimumab in patients with high-risk resectable NSCLC, and will facilitate a… Expand
ConditionsNon-Small Cell Lung Cancer
InterventionDrug
Interventional Clinical Trial
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy. Despite complete resection of early-stage disease recurrence rates in ACC are very high (60%.70%). Patients with Ki67 ≥ 10… Expand
ConditionsAdrenocortical Carcinoma
InterventionDrug, Other
Interventional Clinical Trial
This is a research study to test the effectiveness of nab-paclitaxel + carboplatin + MPDL3280A for treatment of non-small-cell lung carcinoma (NSCLC), which is a type of lung… Expand
ConditionsCarcinoma, Non-Small-Cell Lung
InterventionDrug
Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer
TLDR
It is demonstrated that patients can benefit from the adjuvant chemotherapy in terms of OS and disease-free survival and uracil-tegafur seems to have no advantage in prolonging DFS, unless it is administered with platinum-based therapy. Expand
Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?
TLDR
The recent results of biological programmes indicate that the expression of some tumour markers including ERCC1 be evaluated in order to determine which patients are more likely to benefit from chemotherapy, and tailored therapy might be the next progress for resected NSCLC. Expand
Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?
  • T. le Chevalier
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2010
TLDR
The recent results of biological programmes indicate that the expression of some tumour markers including ERCC1 be evaluated in order to determine which patients are more likely to benefit from chemotherapy, and tailored therapy might be the next progress for resected NSCLC. Expand
Developments in the treatment of early NSCLC: when to use chemotherapy.
  • B. Besse, T. le Chevalier
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2012
TLDR
The Lung adjuvant Ciplatin Evaluation pooled analysis confirmed the substantial effect of postoperative CT, with or without postoperative radiotherapy, with a substantial overall benefit of 4% at 5 years and suggested that the combination of vinorelbine and cisplatin was of more benefit than older two and three drug combinations. Expand
Effectiveness and toxicity of adjuvant chemotherapy in patients with non-small cell lung cancer
TLDR
The results support the benefit of AC for NSCLC patients in a real-world setting, and because the cisplatin-vinorelbine regimen was associated with alarming rates of toxicity, more effective and less toxic alternatives should be investigated. Expand
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer.
TLDR
The results of the International Adjuvant Lung Cancer Trial study confirm the significant efficacy of adjuvant chemotherapy at 5 years and underscores the need for the long-term follow-up of other adjuant lung cancer trials and for a better identification of patients deriving long- term benefit from adjUvant chemotherapy. Expand
Meta-analysis of postoperative adjuvant chemotherapy without radiotherapy in early stage non-small cell lung cancer
TLDR
It is demonstrated that postoperative chemotherapy without radiotherapy improves survival of stage I–II, I, and IB non-small cell lung cancer patients, but not for IA. Expand
Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
TLDR
Cisplatin was confirmed to be slightly superior to carboplatin and is still the drug of choice in the adjuvant setting and the integration of immunotherapy in platinum-based schedules has just started to be evaluated, representing a potential future clinical option, but still far from clinical practice. Expand
Adjuvant and Neoadjuvant Chemotherapy for Early-Stage Nonsmall Cell Lung Cancer
TLDR
Results from a large prospective placebo-controlled study showed no benefit from the use of adjuvant epidermal growth factor (EGFR) tyrosine kinase inhibitor erlotinibs (TKIs), but the study was not designed specifically for patients with tumors harboring EGFR mutations. Expand
[Effect of Adjuvant Chemotherapy on DFS for Patients with Stage I NSCLC].
TLDR
Postoperative chemotherapy does not have a positive effect on DFS in early stage non-small cell lung cancer, and chemotherapy may not be appropriate even for patients with multiple risk factors. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials.
TLDR
This is the first updated meta-analysis demonstrating the importance of cisplatin-based chemotherapy and single-agent UFT therapy as adjuvant chemotherapy in the treatment of resected NSCLC. Expand
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
TLDR
Cisplatin-based adjuvant chemotherapy improves survival among patients with completely resected non-small-cell lung cancer and had a significantly higher survival rate than those assigned to observation. Expand
Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
TLDR
It is found that combination chemotherapy consisting of cisplatin plus a new agent yields a substantial survival advantage compared with carboplatin plusA new agent in patients with advanced NSCLC, although it is failed to find any survival difference in an analysis that included both new and old agents. Expand
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
TLDR
Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer. Expand
Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.
  • D. Waller, M. Peake, +5 authors S. Spiro
  • Medicine
  • European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • 2004
TLDR
This trial has failed to observe a survival benefit with adjuvant chemotherapy following complete resection of stage I-III NSCLC, but the hazard ratio and 95% confidence intervals are consistent with the previously reported meta-analysis and two large recently reported trials, which suggest a small survival Benefit with cisplatin-based chemotherapy. Expand
Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis.
TLDR
Postoperative chemotherapy is associated with improved survival compared with that after surgical intervention alone, and selected patients with completely resected non-small cell lung cancer should be offered chemotherapy. Expand
Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review
TLDR
There was no evidence of a difference in overall survival with neo-adjuvant chemotherapy, but the result is statistically consistent with previous trials, and therefore adds considerable weight to the current evidence. Expand
Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature.
TLDR
The meta-analysis shows the efficacy of adjuvant chemotherapy in stages I and II resected NSCLC, and more data is needed to confirm such a role for induction chemotherapy. Expand
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
TLDR
Adjuvant vinorelbine plus cisplatin extends survival in patients with completely resected NSCLC, better defining indication of adjuvant chemotherapy. Expand
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
TLDR
The results of this meta-analysis suggest that chemotherapy may have a role in treating non-small cell lung cancer, and reached conventional levels of significance when used with radical radiotherapy and with supportive care. Expand
...
1
2
3
4
...